ESMO TAT 2021 | Pan-FGRF inhibitors in different FGFR alteration types across solid tumours

Cedric Pobel, MD, Gustave Roussy Institute, Villejuif, France, shares results from 4 different Phase I/II clinical trials (NCT01703481, NCT01004224, NCT02052778, and NCT01004224), which assessed how different fibroblast growth factor receptor (FGFR) alteration types affect treatment of various cancers. A total of 92 patients were treated with pan-FGRF inhibitors, and patients with FGFR amplifications demonstrated shorter progression-free survival (PFS) and lower response rates. However, one patient with breast cancer and FGFR amplification had an above-average PFS of 7 months. Overall, patients with cholangiocarcinoma and urothelial cancer had the best responses to treatment. This interview took place during the ESMO TAT 2021 conference.